Digestive Disease $22_{\text {Week }}$
Fact or Myth: Black Patients Do Not Want to Participate in Clinical Trials
K. MILLS, MD1; P. ADAMSON, MD1; B. RENELUS, MD ${ }^{1}$; L. CARROLL, MS, MPH2; S. FRANSEN, MSC²; C. XU, PHD2; H. NYINA-MUNTU, RN¹; E. EKPO 1 ; P. PEMU MD, MSCR¹; T. LEVIN, MD³; A. SHAUKAT, MD, MPH ${ }^{4}$; J. LIU, MD ${ }^{1}$
${ }^{1}$ Morehouse School of Medicine, Atlanta, GA; ${ }^{2}$ Freenome Inc, South San Francisco, CA; ${ }^{3}$ Kaiser Permanente Division of Research, Oakland, CA; ${ }^{4} \mathrm{NYU}$ Grossman School of Medicine, New York, NY MAY 21-24. SAN DIEGO, CA

## PURPOSE / OBJECTIVES

Underrepresentation of minority groups, particularly Black individuals, has been a major
issue for most tainical trials issue for most clinical trials
A commonly cited reason is mistrust amongst Black individuals due to historical abuse
At a listorically Black College and University (HBCU) in a maior metronolitan ara wit
 trial compared to other study sites with primarily White patient population

## MATERIAL \& METHODS

- In April 2021, a large prospective, multi-center clinical trial designed to validate a multiomics blood test for early detection of CRC (PREEMPT CRC) was initiated at a HBCU To optimize study recruitment:

Hiturally-ses ine the racilly congruent recruitment staff
Synchronized timing of consent/study procedures with pre-endoscopy COVID testing and ic visits
Evaluated eligible participants screened for a 7 -month period
Enrollment numbers for the HBCU and other study sites compared
-graphic data collected for the enrolled and not enrolled

| Recruitment | Blood Test | Colonoscopy | Study Endpoints |
| :---: | :---: | :---: | :---: |
| $\stackrel{\circ}{\circ} \mathrm{\circ} \circ \stackrel{\circ}{\circ} \circ \circ \circ$ | URO | $\sqrt{5}$ |  |
| $45-85$ years of age, at average risk for CRC scheduled to undergo a routine screening colonoscopy | Enrolled patients provide a sample through a standard blood draw prior to bowel preparation | Enrolled patients undergo standard-ofcare screening colonoscopy | Secondary: Sensitivity for advanced adenoma and negative and positive predictive value for $C R C$ detection Compared to colonoscopy with histopathology as the reference method |

## RESULTS

- During the 7 -month evaluation period, the number of participants enrolled at the HBCU site ( $\mathrm{N}=229$ ) was significantly higher than the average number enrolled across the other 168 sites $\mathrm{N}=90, \mathrm{p}<0.0001$ )
- The HBCU site ranked at the top $11^{\text {th }}$ percentile for participants enrollment across all study - Sites The main difference between the HBCU site and other study sites was race: participants at the HBCU were $86.6 \%$ Black and $4.3 \%$ White, while at the other sites, the participants were $12.0 \%$ Black and $71.5 \%$ White (p<0.0001) Comparison of demographic characteristics and socio-demographic data of the enrolled and not-enrolled subjects at the HBCU were similar (Table 1) and did not identify factors that affect participation in clinical trials


## RESULTS

| RESULTS |  |  |  |
| :---: | :---: | :---: | :---: |
| Table 1. Baseline Patient Demographic and Sociodemographic Information |  |  |  |
|  | Not Enrolled | Enrolled |  |
|  | $\mathrm{n}=257$ | $\mathrm{n}=229$ | p-value |
| Female | 145 (56.4\%) | 134 (58.5\%) | 0.64 |
| Age | $57.6 \pm 7.4$ | $57.5 \pm 7.0$ | 0.87 |
| BMI | $31.5 \pm 8.4$ | $31.8 \pm 8.6$ | 0.77 |
| Race |  |  | 0.75 |
| African American | 226 (87.9\%) | 202 (88.2\%) |  |
| Asian | 2 (0.8\%) | 4 (1.7\%) |  |
| Caucasian | 14 (5.4 \%) | 12 (5.2\%) |  |
| Hispanic | 14 (5.4 \%) | 11 (4.8\%) |  |
| Other/Unk | 1 (0.4\%) | 0 (0.0 \%) |  |
| Marital Status |  |  | 0.55 |
| Div/Sep/Wid | 80 (31.1\%) | 70 (31.7\%) |  |
| Married | 42 (16.3\%) | 45 (20.4\%) |  |
| Other/Unk | 8 (3.1 \%) | 4 (1.8\%) |  |
| Single | 127 (49.4\%) | 102 (46.2\%) |  |
| Christian | 192 (74.7\%) | 173 (77.9\%) | 0.41 |
| Insurance Type |  |  | 0.17 |
| Medicaid | 34 (13.3\%) | 27 (12.2\%) |  |
| Medicare | 35 (13.7\%) | 25 (11.3\%) |  |
| Medicare/Medicaid | 0 (0.0\%) | 5 (2.3\%) |  |
| None | 117 (45.7\%) | 101 (45.7\%) |  |
| Private(Commercial) | 70 (27.3\%) | 63 (28.5\%) |  |

RESULTS
Figure 1. HBCU enrollment in top $11 \%$ of all study sites in PREEMPT CRC


Figure 2. Race comparison of HBCU participants to overall participants enrolling in PREEMPT CRC 90


## SUMMARY / CONCLUSION

- A HBCU site, with predominant Black patient population, was a top enroller among study sites in PREEMPT CRC, a large prospective, multi-center study of a multiomics blood test sites in PREEMPT CRC, a large
for average-risk CRC screening
The finding of our study highlights the importance of providing access to Black individuals to clinical trials to ensure adequate representation in research studies


## 

The authors gratefully acknowledge the participants of PREEMPT CRC as well as Edward Elhauge and Yontao Lu
for their data and statistics support.

 8

Scan for Abstract

